Janus Henderson Global Life Sciences Fund (JNGLX) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.83: the stock has moved about 17% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerJanus Henderson Global Life Sciences Fund (JNGLX) trades at $86.09. Janus Henderson Global Life Sciences Fund (JNGLX) is a non-diversified fund focusing on life science companies. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for JNGLX: JNGLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Janus Henderson Global Life Sciences Fund (JNGLX) Financial Services Profile
Janus Henderson Global Life Sciences Fund (JNGLX) is a specialized fund concentrating on life science companies, leveraging its expertise in the healthcare sector. With a focus on long-term capital appreciation, the fund navigates the complexities of the global life sciences market, offering investors targeted exposure to this dynamic industry.
What Is the Investment Thesis for JNGLX?
Janus Henderson Global Life Sciences Fund (JNGLX) presents an investment opportunity for those seeking targeted exposure to the life sciences sector. With a market capitalization of $5.60 billion and a beta of 0.83, the fund exhibits moderate volatility relative to the broader market. The fund's strategy of investing at least 25% of its assets in core life sciences companies provides a focused approach to capturing growth in this sector. Key catalysts include advancements in biotechnology, pharmaceutical innovation, and increasing healthcare spending globally. However, potential risks include regulatory hurdles, patent expirations, and competition from other funds with similar investment objectives. The absence of a dividend yield may deter income-seeking investors.
Based on FMP financials and quantitative analysis
JNGLX Key Highlights
The fund maintains a focused investment strategy, allocating at least 80% of its net assets to companies with a life science orientation.
- A minimum of 25% of the fund's total assets are invested in companies categorized within the 'life sciences' sector, ensuring targeted exposure.
- With a market capitalization of $5.60 billion, JNGLX demonstrates substantial scale within the asset management landscape.
- The fund's beta of 0.83 indicates moderate volatility compared to the broader market, potentially appealing to risk-conscious investors.
- JNGLX does not offer a dividend yield, which may be a consideration for income-focused investors.
Who Are JNGLX's Competitors?
JNGLX is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CTCAX Columbia Global Technology Growth Fund | $138.28 | +1.13% | $6.27B | — |
| FHASX Fidelity Freedom Blend 2035 Fund | $14.63 | +0.34% | $5.40B | — |
| FTRNX Fidelity Trend Fund | $224.59 | +1.13% | $5.19B | — |
| JDWNX Janus Henderson Global Research Fund | $134.49 | +0.67% | $4.77B | — |
| APO Apollo Global Management, Inc. | $115.35 | +1.17% | $66.4B | 55 5-pillar |
| ALTI AlTi Global, Inc. | $2.88 | -1.20% | $427M | — |
| GROW U.S. Global Investors, Inc. | $2.94 | +2.80% | $37.3M | 57 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JNGLX's Key Strengths?
Focused investment strategy in the high-growth life sciences sector.
- Experienced management team with expertise in healthcare and biotechnology.
- Established track record of managing investment portfolios.
- Rigorous research process to identify promising investment opportunities.
What Are JNGLX's Weaknesses?
Non-diversified fund, which may increase volatility.
- Concentration in the life sciences sector, which may be subject to regulatory and competitive pressures.
- Absence of a dividend yield, which may deter income-seeking investors.
- Dependence on the performance of a relatively small number of companies.
What Are the Key Risks for JNGLX?
Regulatory setbacks for pharmaceutical and biotechnology companies.
- Patent expirations and generic competition.
- Market volatility and economic downturns.
- Competition from other specialized healthcare and biotechnology funds.
What Are JNGLX's Competitive Advantages?
- Expertise in the life sciences sector, providing a deep understanding of industry trends and investment opportunities.
- Established track record of managing investment portfolios for a wide range of clients.
- Rigorous research process and disciplined investment approach.
- Access to a global network of industry experts and analysts.
What Does JNGLX Do?
Janus Henderson Global Life Sciences Fund (JNGLX) is a non-diversified fund managed by Janus Henderson Investors. The fund's primary objective is to seek long-term capital appreciation by investing in companies with a life science orientation. Under normal circumstances, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio manager believes have a life science orientation. A fundamental policy of the fund is to normally invest at least 25% of its total assets in securities of companies that are categorized in the 'life sciences' sector. This includes companies involved in pharmaceuticals, biotechnology, medical devices, and related fields. The fund's investment strategy involves identifying companies with strong growth potential, innovative products or services, and sound management teams. The portfolio manager employs a rigorous research process to evaluate investment opportunities and construct a portfolio that reflects the fund's investment objective. The fund may invest in companies of any size, from small-cap to large-cap, and may also invest in foreign securities. The fund's non-diversified status means that it may invest a significant portion of its assets in a relatively small number of companies, which may increase the fund's volatility. Janus Henderson Investors is a global asset manager with a long history of managing investment portfolios for individuals, institutions, and financial intermediaries. The firm offers a wide range of investment strategies across various asset classes, including equities, fixed income, and alternatives.
What Products and Services Does JNGLX Offer?
- Invests in securities of companies with a life science orientation.
- Targets companies involved in pharmaceuticals, biotechnology, and medical devices.
- Seeks long-term capital appreciation through strategic investments.
- Conducts rigorous research to identify promising investment opportunities.
- May invest in companies of any size, from small-cap to large-cap.
- May invest in foreign securities to diversify its portfolio.
- Operates as a non-diversified fund, concentrating investments in specific areas.
How Does JNGLX Make Money?
- Generates revenue through management fees charged on assets under management (AUM).
- Aims to outperform its benchmark by selecting high-performing life science companies.
- Utilizes a research-driven investment approach to identify promising opportunities.
- Manages risk through diversification within the life sciences sector.
What Industry Does JNGLX Operate In?
Janus Henderson Global Life Sciences Fund operates within the global asset management industry, specifically targeting the life sciences sector. The asset management industry is characterized by intense competition, with numerous firms offering a wide range of investment products and services. The life sciences sector is driven by innovation in biotechnology, pharmaceuticals, and medical devices, with significant growth potential due to aging populations and increasing healthcare spending globally. The fund competes with other specialized healthcare and biotechnology funds, as well as broader market index funds.
Who Are JNGLX's Key Customers?
- Individual investors seeking exposure to the life sciences sector.
- Institutional investors looking for specialized investment strategies.
- Financial advisors seeking to diversify client portfolios.
- Retirement plans and endowments seeking long-term growth.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a fund, not an operating company
JNGLX Financials
Bull Case vs Bear Case
Bull Case
- Focused investment strategy in the high-growth life sciences sector.
- Experienced management team with expertise in healthcare and biotechnology.
- Established track record of managing investment portfolios.
- Rigorous research process to identify promising investment opportunities.
Bear Case
- Non-diversified fund, which may increase volatility.
- Concentration in the life sciences sector, which may be subject to regulatory and competitive pressures.
- Absence of a dividend yield, which may deter income-seeking investors.
- Dependence on the performance of a relatively small number of companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
JNGLX Latest News
No recent news available for JNGLX.
JNGLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for JNGLX.
Price Targets
Wall Street price target analysis for JNGLX.
JNGLX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for JNGLX; grades run from A+ (80-100) to F (below 30).
What Investors Ask About Janus Henderson Global Life Sciences Fund (JNGLX) — Financials
What is the expense ratio for JNGLX, and how does it compare to similar funds?
The expense ratio represents the annual cost of operating the fund, expressed as a percentage of the fund's average net assets. A lower expense ratio is generally more favorable for investors, as it means that more of the fund's returns are passed on to shareholders.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.